文献速递消化道肿瘤放疗放疗物理与技术

HEATPAC:局部晚期胰腺癌热化放疗与单纯化放疗的II期随机研究

"HEATPAC" - a phase II randomized study of concurrent thermochemoradiotherapy versus chemoradiotherapy alone in locally advanced pancreatic cancer.
PubMed 文献 · Radiat Oncol · 2017-11-21

HEATPAC是一项在不可切除局部晚期胰腺癌中开展的II期随机试验,比较同步热化放疗(HTCTRT)与单纯化放疗(CTRT)的可行性和疗效,两组均联合FOLFIRINOX方案。研究计划入组86例患者,主要预期HTCTRT较CTRT的1年总生存率提高20%。

要点

  • 不可切除局部晚期胰腺癌在4周期FOLFIRINOX诱导后随机接受单纯化放疗或联合区域热疗。
  • 放疗采用同步整合加量调强放疗,肿瘤区56Gy、临床靶区50.4Gy,分28次5.5周完成。
  • 热疗每周1次共6次,目标温度40-43℃持续60分钟,需实时十二指肠内多传感器测温监测。

核心结论

  • 该II期随机研究旨在评估同步热化放疗较单纯化放疗在不可切除局部晚期胰腺癌中的可行性和疗效。

研究设计与样本

  • II期随机试验,计划将86例不可切除局部晚期胰腺癌患者等额随机分入HTCTRT组和CTRT组。
  • 入组患者先接受4周期标准剂量和方案的FOLFIRINOX诱导,无转移且无肉眼腹膜癌病者方可随机。

主要发现

  • 原文未报告研究结果,仅描述设计及预期:单纯CTRT的1年基线总生存率考虑为40%,HTCTRT预期生存获益+20%。

关键数值与推荐

  • 对照组接受同步CTRT联合吉西他滨400 mg/m2每周×6次。
  • 研究组在对照组CTRT基础上联合区域热疗每周×6次(放疗期间),每次目标40-43℃持续60分钟。
  • 放疗为同步整合加量调强放疗,肿瘤区56Gy、临床靶区50.4Gy,分28次5.5周完成。
  • 化放疗/热化放疗完成后,两组均再接受8周期FOLFIRINOX。
  • 样本量计算取α=0.05、β=0.80,共86例等额随机。

临床怎么用

  • 该方案将热疗作为放疗和吉西他滨的三重增敏手段,探索不可切除局部晚期胰腺癌的治疗策略。
  • 热疗需每周实施并以实时十二指肠内多传感器测温探头监测,目标温度40-43℃持续60分钟。

局限性

  • 原文为研究方案描述,尚未报告可行性、安全性或疗效结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pancreatic cancer has a dismal prognosis with 5-year overall survival rate of around 5%. Although surgery is still the best option in operable cases, majority of the patients who present in locally advanced stages are deemed inoperable. Novel approaches are therefore needed for the management of around 80% of these inoperable locally advanced pancreatic cancers (LAPC). Hyperthermia (39-43 °C) is a potent radiosensitizer and further enhances the action of gemcitabine, also a known radiosensitizer. Thus through triple sensitization, a combination of hyperthermia, radiotherapy and gemcitabine could be expected to improve the therapeutic outcomes in LAPC. METHODS: This phase II randomized trial, HEATPAC in unresectable LAPC, explores the feasibility and efficacy of concurrent thermochemoradiotherapy (HTCTRT) over chemoradiotherapy (CTRT) alone with pre- and post-intervention FOLFIRINOX at standard dosage and schedule. Following 4 cycles of neoadjuvant FOLFIRINOX, patients with no metastasis and absence of gross peritoneal carcinomatosis would be randomized to either (a) control arm: concurrent CTRT with gemcitabine (400 mg/m2, weekly ×6) or (b) study arm: locoregional hyperthermia (weekly ×6 during radiotherapy) with concurrent CTRT (same as in control arm). All patients would receive simultaneous-integrated boost intensity-modulated radiation therapy to doses of 56Gy and 50.4Gy to the gross and clinical target volumes respectively delivered in 28 fractions over 5.5 weeks. Deep locoregional hyperthermia would be administered weekly and monitored with real-time intraduodenal multisensor thermometry probe. A temperature of 40-43 °C for 60 min would be aimed for each hyperthermia session. On completion of CTRT/HTCTRT, patients of both groups would receive an additional 8 cycles of FOLFIRINOX. DISCUSSION: The expected 1-year baseline overall survival with CTRT alone is considered as 40%. With HTCTRT, a survival advantage of +20% is expected. Considering α = 0.05 and β = 0.80 for sample size computation, a total of 86 patients would be equally randomized into the two treatment groups. This phase II study if found to be safe and effective, would form the basis of a future phase III randomized study. TRIAL REGISTRATION: The trial has been registered with the ClinicalTrials.gov ( NCT02439593 ). The study has been approved by the Ethical Commissions of Basel and Zurich and is open for patient recruitment.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Datta NR, Pestalozzi B, Clavien PA, et al. "HEATPAC" - a phase II randomized study of concurrent thermochemoradiotherapy versus chemoradiotherapy alone in locally advanced pancreatic cancer. Radiat Oncol. 2017. PMID: 29162142. doi:10.1186/s13014-017-0923-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。